Key Highlights

• It would re-enrich depleted uranium hexafluoride tails from past enrichment operations to natural levels and enrich natural-grade uranium hexafluoride to a maximum of 8% U-235.

• It owns and licenses its laser-based isotope separation technology, SILEX, and holds 51% of GLE, which has the exclusive rights to commercialise the technology for uranium enrichment.

• The net loss narrowed to $38.6 million from $42.6 million, helped by higher Revenue and interest income and partly offset by a larger share of GLE losses and higher employee costs.

• GLE received US$28.5 million from the US Department of Energy in January 2026 (per the American Nuclear Society).

What does a regulator's final environmental report change for a technology company that has no commercial enrichment plant yet? For Silex Systems Limited (ASX:SLX), the answer is a clearer path, not a finished one. In late October 2026, the US Nuclear Regulatory Commission (NRC) released the final environmental impact statement (EIS) for the proposed Paducah Laser Enrichment Facility in Kentucky, which Silex's 51%-owned joint venture, Global Laser Enrichment (GLE), plans to build. Silex and GLE say the EIS supports issuing a licence to begin construction, but the NRC still has a safety review to complete.

The central development

According to the American Nuclear Society's report dated 27 October 2026, the final EIS follows a draft issued for public comment on 27 March 2026. GLE completed its licence application in July 2025. Silex expects the NRC's safety evaluation report (SER) before the end of contract year 2026 and licence approval in 2027, with GLE planning to begin operations in 2030. These are company expectations, not regulatory commitments, and the licensing timetable could change.

The proposed plant would sit on a 665-acre site next to the former Paducah Gaseous Diffusion Plant, acquired in November 2024. It would re-enrich depleted uranium hexafluoride tails from past enrichment operations to natural levels and enrich natural-grade uranium hexafluoride to a maximum of 8% U-235. The planned output is up to 2,000 metric tons per year of equivalent natural UF6 and up to 6 million separative work units (SWUs) per year of low-enriched uranium. The EIS rated effects on surface water, ecology, transportation and socioeconomics as small to medium, with socioeconomic effects mostly positive, and small effects in all other categories.

What Silex actually owns

Silex does not generate meaningful revenue from selling uranium. It owns and licenses its laser-based isotope separation technology, SILEX, and holds 51% of GLE, which has the exclusive rights to commercialise the technology for uranium enrichment. Silex's financial return from the project therefore depends on GLE building and operating a plant and on GLE's cash flows, as well as on milestone and licensing payments linked to technology progress. Silex also has a separate silicon enrichment program, Q-Si, aimed at supplying enriched silicon for quantum computing; a plant in Sydney has been built and commissioning is under way, with completion expected in late 2026 and sample production expected in early 2027, per the company's FY26 summary.

FY26 financial results

The net loss narrowed to $38.6 million from $42.6 million, helped by higher revenue and interest income and partly offset by a larger share of GLE losses and higher employee costs. Cash and term deposits were $180.7 million at 30 June 2026, with no corporate debt, and net Assets were $201.2 million. Silex raised $130 million in an institutional Placement and $19.4 million through a share purchase plan. No Dividend was declared.

Funding and government support

GLE received US$28.5 million from the US Department of Energy in January 2026 (per the American Nuclear Society). In March 2026, Kentucky and McCracken County gave preliminary approval to an incentive package valued at up to about US$98.9 million. A final Investment decision and project financing remain important unknowns.

Sector and competitive position

Global enrichment capacity is concentrated among a few incumbents, including Rosatom, Urenco and Orano, and Western utilities have been seeking non-Russian Supply of low-enriched uranium. This policy backdrop has favoured new US enrichment projects, and several companies are pursuing next-generation approaches. Laser enrichment is theoretically more efficient than centrifuges, but it is unproven at commercial scale. Silex's next technical milestone is TRL-7, which would involve demonstrating the technology in an operational environment; the company has described this as its near-term goal, with commercial operation by 2030 subject to feasibility, licensing and market conditions.

Risks and what to monitor

Key risks include licensing delay or conditions; technology scale-up from pilot to commercial; funding and cost overruns; changes to US energy and nuclear policy; competition from other enrichment technologies and from Russian supply returning to markets; GLE partner and offtake arrangements; and the long timeline to first revenue in 2030 or later. Because Silex equity-accounts for its share of GLE losses, GLE's spending will continue to flow into Silex's reported results.

In summary, the final EIS removes one regulatory uncertainty, but the company remains a pre-commercial technology developer. The licence decision, funding and demonstration at scale will matter more to its long-term outcome than any single approval.